Summary
Sustained cough is a frequent complaint in methotrexate (MTX) treatment for rheumatoid arthritis and can be a symptom of incipient MTX-induced pneumonitis. This study was performed to characterize MTX-associated cough clinically and to clarify by which means this condition can be distinguished from incipient MTX pneumonitis.
Three patients with MTX-induced pneumonitis and 10 patients with sustained cough unassociated with pneumonitis were examined clinically, by pulmonary function testing, and bronchoalveolar lavage (BAL). In MTX pneumonitis, cough was associated with progressive dyspnoea, constitutional symptoms, impaired pulmonary function, and interstitial infiltration of variable degree by chest X-ray. BAL cytology invariably showed lymphocytic alveolitis while transbronchial biopsy revealed active interstitial inflammation in only one patient. Ten patients had sustained, nonprogressive cough in the absence of constitutional symptoms, progressive dyspnoea and impaired pulmonary function. Neither X-ray nor BAL nor transbronchial biopsy revealed any evidence of interstitial lung disease. In the majority of these patients, cough abated with symptomatic treatment with or without temporary discontinuation of MTX.
It is concluded that MTX-associated cough can be a reflection of isolated airway disease. Clinically, absence of constitutional symptoms, impaired pulmonary function, and interstitial infiltration on X-ray distinguished this condition from incipient MTX pneumonitis. Cough without pulmonary parenchymal involvement appears to result from an irritant effect of MTX on the airways.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schnabel, A., Gross, W. L. Low-dose methotrexate in rheumatic diseases- efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994, 23, 310–327.
Barrera, P., Laan, F.J.M., van Riel, P.L.C.M., Dekhuijzen, P.N.R., Boerbooms, A.M.T., van de Putte, L.B.A. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994, 53, 434–439.
Cannon, G.W., Ward, J.R., Clegg, D.O., Samuelson, Jr. C. O., Abbott, T.M. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983, 26, 1269–1274.
Engelbrecht, J.A., Calhoon, S.L., Scherrer, J.J. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 1983, 26, 1275–1278.
St. Clair, E.W., Rice, J.R., Snyderman, R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Int Med 1985, 145, 2035–2038.
Searles, G., McKendry, R.J.R. Methotrexate pneumonitis in rheumatoid arthritis: Potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987, 14, 1164–1171.
Hargreaves, M., Mowat, A.G., Benson, M.K. Acute pneumonitis associated with low-dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992, 47, 628–633.
Weinblatt, M.E., Kaplan, H., Germain, B.F., Merriman, R.C., Solomon, S.D., Wall B., Anderson, L., Block, S., Irby, R., Wolfe, F., Gall, E., Torretti, D., Biundo, J., Small, R., Coblyn, J., Polisson, R. Low-dose methotrexate compared with auranofin in adult rheumtoid arthritis. Arthritis Rheum 1990, 33, 330–338.
Shiroky, J.B., Neville, C., Esdaile, J.M., Choquette, D., Zummer, M., Hazeltine M., Bykerk, V., Kanji, M., St-Pierre, A., Robidoux, L., Bourque, L. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1993, 36, 795–803.
Fehlauer, C.S., Carson, C.W., Cannon, G.W., Ward, J.R., Samuelson, C.O., Williams H.J., Clegg, D.O. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective follow-up study. J Rheumatol 1989, 16, 307–312.
Sany, J., Anaya, J.M., Lussiez, V., Couret, M., Combe, B., Daures, J.-P. Treatment of rheumatoid arthritis with methotrexate: A prospective open longterm study of 191 cases. J Rheumatol 1991, 18, 1323–1327.
Herborn, G., Rau, R., Menninger, H., Elhardt, D., Schmitt, J. Zweijahresdaten der Vergleichsstudie Methotrexat/Aurothiomalat von 102 Patienten. Z Rheumatol 1992, 51, 163–171.
Wolfe, F., Cathey, M.A. The effect of age on methotrexate efficacy and toxicity. J Rheumatol 1991, 18, 937–977.
Schnabel, A., Herlyn, K., Gross, W.L. Long-term tolerability of methotrexate MTX at doses exceeding 15 mg/week in rheumatoid arthritis. Rheumatol Int 1996, 15, 195–200.
Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., Medsger, T.A., Mitchell, D.M., Neustadt, D.H., Pinals, R.S., Schaller, J.G., Sharp, J.T., Wilder, R.L., Hunder, G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1987, 31, 315–324.
European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome: Preliminary Criteria for the Classification of Sjögren's Syndrome. Arthritis Rheum 1993, 36, 340–347.
Carson, C.W., Cannon, G.W., Egger, M.J., Ward, J.R., Clegg, D.O. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthrititis Rheum 1987, 16, 186–195.
Cook, N.J., Carroll, G.J. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis. Ann Rheum Dis 1992, 51, 272–274.
Golden, M.R., Katz, R.S., Balk, R.A., Neu, J., Golden, H. The relationship of preexisting lung disease to the occurrence of methotrexate pneumonitis in rheumatoid arthritis patients. Arthritis Rheum 1990, 33 Suppl, S40.
Carroll, G.J., Thomas, R., Phatouros, C.C., Atchison, M.H., Leslie, A.-L., Cook, N.J., DaSouza, I. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994, 12, 51–54.
Ridley, M.G., Wolfe, C.S., Mathews, J.A. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988, 47, 784–788.
White, D.A., Rankin, J.A., Stover, D.E., Gellene, R.A., Gupta, S. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Resp Dis 1989, 139, 18–21.
Akoun, G.M., Gauthier-Rahman, S., Mayaud, C., Touboul, J.L., Denis, M.F. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 1987, 91, 96–99.
Pourel, J., Guillemin, F., Fener, P., Webanck, L., Bene, M.-C., Delorme, N. Delayed methotrexate pneumonitis in rheumatoid arthritis. J Rheumatol 1991, 18, 303–304.
Costabel, U., Bross, K.J., Matthys, H. Diagnosis by bronchoalveolar lavage of cause of pulmonary infiltrates in haematological malignancies. Brit Med J 1985, 290, 1041.
Jones, G., Mierins, E., Karsh, J. Methotrexate induced asthma. Am Rev Resp Dis 1991, 143, 179–181.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schnabel, A., Dalhoff, K., Bauerfeind, S. et al. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 15, 277–282 (1996). https://doi.org/10.1007/BF02229707
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02229707